Overview

Afatinib Expanded Access Program

Status:
Approved for marketing
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center, single-arm trial, designed to provide early access to afatinib and to provide additional information on the safety and efficacy of afatinib in advanced NSCLC patients who harbor an EGFR mutation.
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Afatinib